denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Geron Corporation, Incyte Corporation, Protagonist Therapeutics
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Workforce, Diseases, Therapies, Adverse Events, Biological Processes
Hematology Disease Topics & Pathways:
Research, Workforce, Diseases, Therapies, Adverse Events, Biological Processes
Friday, December 8, 2023: 11:00 AM-2:00 PM
Room 6B
(San Diego Convention Center)
Chair:
Andrew T. Kuykendall, MD, Moffitt Cancer Center
Disclosures:
Kuykendall: Blueprint: Consultancy, Research Funding, Speakers Bureau; Morphosys: Consultancy, Research Funding; Prelude: Research Funding; BMS: Consultancy, Research Funding; Protagonist Therapeutics, Inc.: Consultancy, Research Funding; Sierra Oncology: Research Funding; AbbVie: Consultancy; CTI: Consultancy; GSK: Consultancy; Imago: Consultancy; Incyte: Consultancy; Novartis: Consultancy.
Speakers:
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center
,
Barbara Mora, MD, Division of Hematology, Ospedale ASST Sette Laghi, University of Insubria
and
Gabriela S. Hobbs, MD, Massachusetts General Hospital
Disclosures:
Pemmaraju: Aplastic Anemia & MDS International Foundation: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Patient Power: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pacylex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CancerNet: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cimeio Therapeutics AG: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Blueprint: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; United States Department of Defense (DOD): Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASH Committee on Communications: Other: Leadership; OncLive: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Physician Education Resource (PER): Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; Aptitude Health: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Curio Science: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PeerView Institute for Medical Education: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ImmunoGen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; EUSA Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CareDx: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Dava Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Harborside Press: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Imedex: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Magdalen Medical Publishing: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ClearView Healthcare Partners: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Protagonist Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Neopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Intellisphere: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Medscape: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASCO Cancer.Net Editorial Board: Other: Leadership; Karger Publishers: Other: Licenses; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; HemOnc Times/Oncology Times: Other: Uncompensated; Bristol Myers Squibb Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Mora: Novartis: Honoraria. Hobbs: Keros: Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Pharmaxis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Regeneron: Current holder of stock options in a privately-held company; Protagonist: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees, Research Funding.
The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2023 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with myeloproliferative neoplasms (MPNs) with novel treatment approaches and emerging treatment strategies in the context of current paradigms.
After each “decision point,” the chair will challenge the faculty member to Show Me the Data! that backs up their decision-making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision-making. ARS will be utilized throughout to identify learners current knowledge and competence levels at the beginning and conclusion of each case scenario.
To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
See more of: Friday Satellite Symposia